株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

HIV治療薬の世界市場:産業動向、市場シェア・規模・成長率・機会・予測

HIV Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2019-2024

発行 IMARC Services Private Limited 商品コード 662781
出版日 ページ情報 英文 102 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=108.55円で換算しております。
Back to Top
HIV治療薬の世界市場:産業動向、市場シェア・規模・成長率・機会・予測 HIV Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2019-2024
出版日: 2019年04月08日 ページ情報: 英文 102 Pages
概要

当レポートでは、世界のHIV治療薬市場について分析し、市場の全体的構造や、市場規模の推移・見通し、薬剤クラス・流通チャネル・地域別の詳細動向、製造工程の概略、主要企業のプロファイルなどについて調査しております。

第1章 序論

第2章 分析範囲・手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 業界の主な動向

第5章 世界のHIV治療薬市場

  • 市場概要
  • 市場の実績
  • 価格分析
  • 市場区分:薬剤クラス別
  • 市場区分:流通チャネル別
  • 市場区分:地域別
  • 市場予測
  • SWOT分析
  • バリューチェーン分析
  • ポーターのファイブフォース分析

第6章 市場区分:薬剤クラス別

  • ヌクレオシド系逆転写酵素阻害薬
  • マルチクラスコンビネーション製品
  • プロテアーゼ阻害剤
  • HIVインテグラーゼ阻害剤
  • 非ヌクレオシド系逆転写酵素阻害薬
  • 侵入阻害剤 - CCR5コレセプター阻害剤
  • 融合阻害剤

第7章 市場区分:流通チャネル別

  • 病院薬局
  • 小売り薬局
  • オンライン薬局
  • その他

第8章 市場区分:地域別

  • 北米
  • 欧州
  • アジア太平洋地域
  • ラテンアメリカ
  • 中東・アフリカ

第9章 HIV治療薬の製造工程

  • 製品概要
  • 原材料の要件
  • 製造工程
  • 主な成功・リスク要因

第10章 競争環境

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Boehringer Ingelheim International GmbH
    • Merck & Co., Inc.
    • ViiV Healthcare
    • AbbVie
    • F. Hoffmann-La Roche Ltd.
    • Teva Pharmaceutical Industries Ltd.
    • Bristol-Myers Squibb
    • Gilead Sciences, Inc.
    • Johnson & Johnson
    • Cipla Limited
    • 第一三共
    • Emcure
    • Hetero Drugs
    • Mylan
図表

List of Figures

  • Figure 1: Global: HIV Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: HIV Drugs Market: Sales Value (in Billion US$), 2011-2018
  • Figure 3: Global: HIV Drugs Market: Breakup by Drug Class (in %), 2018
  • Figure 4: Global: HIV Drugs Market: Breakup by Distribution Channel (in %), 2018
  • Figure 5: Global: HIV Drugs Market: Breakup by Region (in %), 2018
  • Figure 6: Global: HIV Drugs Market Forecast: Sales Value (in Billion US$), 2019-2024
  • Figure 7: Global: HIV Drugs Industry: SWOT Analysis
  • Figure 8: Global: HIV Drugs Industry: Value Chain Analysis
  • Figure 9: Global: HIV Drugs Industry: Porter's Five Forces Analysis
  • Figure 10: Global: HIV Drugs (Nucleoside Reverse Transcriptase Inhibitors) Market: Sales Value (in Million US$), 2011 & 2018
  • Figure 11: Global: HIV Drugs (Nucleoside Reverse Transcriptase Inhibitors) Market Forecast: Sales Value (in Million US$), 2019-2024
  • Figure 12: Global: HIV Drugs (Multi-Class Combination Products) Market: Sales Value (in Million US$), 2011 & 2018
  • Figure 13: Global: HIV Drugs (Multi-Class Combination Products) Market Forecast: Sales Value (in Million US$), 2019-2024
  • Figure 14: Global: HIV Drugs (Protease Inhibitors) Market: Sales Value (in Million US$), 2011 & 2018
  • Figure 15: Global: HIV Drugs (Protease Inhibitors) Market Forecast: Sales Value (in Million US$), 2019-2024
  • Figure 16: Global: HIV Drugs (HIV Integrase Strand Transfer Inhibitors) Market: Sales Value (in Million US$), 2011 & 2018
  • Figure 17: Global: HIV Drugs (HIV Integrase Strand Transfer Inhibitors) Market Forecast: Sales Value (in Million US$), 2019-2024
  • Figure 18: Global: HIV Drugs (Non-Nucleoside Reverse Transcriptase Inhibitors) Market: Sales Value (in Million US$), 2011 & 2018
  • Figure 19: Global: HIV Drugs (Non-Nucleoside Reverse Transcriptase Inhibitors) Market Forecast: Sales Value (in Million US$), 2019-2024
  • Figure 20: Global: HIV Drugs (Entry Inhibitors - CCR5 Co-Receptor Antagonist) Market: Sales Value (in Million US$), 2011 & 2018
  • Figure 21: Global: HIV Drugs (Entry Inhibitors - CCR5 Co-Receptor Antagonist) Market Forecast: Sales Value (in Million US$), 2019-2024
  • Figure 22: Global: HIV Drugs (Fusion Inhibitors and Others) Market: Sales Value (in Million US$), 2011 & 2018
  • Figure 23: Global: HIV Drugs (Fusion Inhibitors and Others) Market Forecast: Sales Value (in Million US$), 2019-2024
  • Figure 24: Global: HIV Drugs Market: Sales through Hospital Pharmacies (in Million US$), 2011 & 2018
  • Figure 25: Global: HIV Drugs Market Forecast: Sales through Hospital Pharmacies (in Million US$), 2019-2024
  • Figure 26: Global: HIV Drugs Market: Sales through Retail Pharmacies (in Million US$), 2011 & 2018
  • Figure 27: Global: HIV Drugs Market Forecast: Sales through Retail Pharmacies (in Million US$), 2019-2024
  • Figure 28: Global: HIV Drugs Market: Sales through Online Pharmacies (in Million US$), 2011 & 2018
  • Figure 29: Global: HIV Drugs Market Forecast: Sales through Online Pharmacies (in Million US$), 2019-2024
  • Figure 30: Global: HIV Drugs Market: Sales through Other Distribution Channels (in Million US$), 2011 & 2018
  • Figure 31: Global: HIV Drugs Market Forecast: Sales through Other Distribution Channels (in Million US$), 2019-2024
  • Figure 32: North America: HIV Drugs Market: Sales Value (in Million US$), 2011 & 2018
  • Figure 33: North America: HIV Drugs Market Forecast: Sales Value (in Million US$), 2019-2024
  • Figure 34: Europe: HIV Drugs Market: Sales Value (in Million US$), 2011 & 2018
  • Figure 35: Europe: HIV Drugs Market Forecast: Sales Value (in Million US$), 2019-2024
  • Figure 36: Asia Pacific: HIV Drugs Market: Sales Value (in Million US$), 2011 & 2018
  • Figure 37: Asia Pacific: HIV Drugs Market Forecast: Sales Value (in Million US$), 2019-2024
  • Figure 38: Middle East and Africa: HIV Drugs Market: Sales Value (in Million US$), 2011 & 2018
  • Figure 39: Middle East and Africa: HIV Drugs Market Forecast: Sales Value (in Million US$), 2019-2024
  • Figure 40: Latin America: HIV Drugs Market: Sales Value (in Million US$), 2011 & 2018
  • Figure 41: Latin America: HIV Drugs Market Forecast: Sales Value (in Million US$), 2019-2024
  • Figure 42: HIV Drugs Manufacturing: Detailed Process Flow
  • Figure 43: Global: HIV Drugs Market: Breakup by Key Players (in %)

List of Tables

  • Table 1: Global: HIV Drugs Market: Key Industry Highlights, 2018 and 2024
  • Table 2: Global: HIV Drugs Market Forecast: Breakup by Drug Class (in Million US$), 2019-2024
  • Table 3: Global: HIV Drugs Market Forecast: Breakup by Distribution Channel (in Million US$), 2019-2024
  • Table 4: Global: HIV Drugs Market Forecast: Breakup by Region (in Million US$), 2019-2024
  • Table 5: HIV Drugs Manufacturing: Raw Material Requirements
  • Table 6: Global: HIV Drugs Market: Competitive Structure
  • Table 7: Global: HIV Drugs Market: Key Players
目次
Product Code: SR1018G83_Report

Human Immunodeficiency Virus (HIV) is a chronic and life-threatening disease which can be transferred from one person to another through blood-to-blood and sexual contact. It is a virus which attacks immune cells known as CD-4 cells, making body susceptible to infections and other diseases. Over the years, the rising prevalence of HIV disease worldwide has positively influenced the demand for HIV drugs. HIV drugs help in preventing the multiplication of HIV virus, thereby reducing the risk of its transmission. According to the latest report by IMARC Group, titled "HIV Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2019-2024", the global HIV drugs market exceeded a value of US$ 24.7 Billion in 2018.

One of the primary factors catalysing the growth of the global HIV drugs market is increase in the prevalence of HIV and its diagnosis. Apart from this, the market is also influenced by a rise in the number of government initiatives for spreading the awareness amongst people regarding causes, symptoms and treatments. Moreover, the introduction of generic drugs, which are cost-effective and chemically identical to branded drugs, act as another factor that is contributing towards the demand for HIV drugs. Looking forward, the market value is projected to reach US$ 22.5 Billion by 2024, declining at a CAGR of 2.5% during 2019-2024.

Market Summary:

  • Based on class, the market has been segmented into multi-class combination products, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, fusion inhibitors, entry inhibitors - CCR5 co-receptor antagonist and HIV integrase strand transfer inhibitors.
  • On the basis of distribution channel, the market is segregated as hospital pharmacies, retail pharmacies, online pharmacies and others. Hospital pharmacies currently account for the largest share.
  • Region-wise, the market has been segmented into Europe, Asia Pacific, North America, Middle East and Africa, and Latin America. Amongst these, North America is the leading market accounting for the majority of the global market.
  • the Competitive Landscape of the market has also been examined with some of the key players being Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson and Merck.
  • This report provides a deep insight into the global HIV drugs market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter's five forces analysis, value chain analysis, etc. This report is a must-read for entrepreneurs, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the HIV drugs market in any manner.

Key Questions Answered in This Report:

  • How has the global HIV drugs market performed so far and how will it perform in the coming years?
  • What are the key regions in the global HIV drugs market?
  • Which are the popular class types in the global HIV drugs market?
  • What are the major distribution channels in the global HIV drugs market?
  • What are the various stages in the value chain of the global HIV drugs market?
  • What are the key driving factors and challenges in the global HIV drugs market?
  • What is the structure of the global HIV drugs market and who are the key players?
  • What is the degree of competition in the global HIV drugs market?
  • How are HIV drugs manufactured?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global HIV Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Price Analysis
  • 5.4 Market Breakup by Drug Class
  • 5.5 Market Breakup by Distribution Channel
  • 5.6 Market Breakup by Region
  • 5.7 Market Forecast
  • 5.8 SWOT Analysis
    • 5.8.1 Overview
    • 5.8.2 Strengths
    • 5.8.3 Weaknesses
    • 5.8.4 Opportunities
    • 5.8.5 Threats
  • 5.9 Value Chain Analysis
    • 5.9.1 Overview
    • 5.9.2 Research and Development
    • 5.9.3 Raw Material Procurement
    • 5.9.4 Manufacturing
    • 5.9.5 Marketing
    • 5.9.6 Distribution
    • 5.9.7 End-Use
  • 5.10 Porters Five Forces Analysis
    • 5.10.1 Overview
    • 5.10.2 Bargaining Power of Buyers
    • 5.10.3 Bargaining Power of Suppliers
    • 5.10.4 Degree of Competition
    • 5.10.5 Threat of New Entrants
    • 5.10.6 Threat of Substitutes

6 Market Breakup by Drug Class

  • 6.1 Nucleoside Reverse Transcriptase Inhibitors
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Multi-Class Combination Products
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Protease Inhibitors
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 HIV Integrase Strand Transfer Inhibitors
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Non-Nucleoside Reverse Transcriptase Inhibitors
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Entry Inhibitors - CCR5 Co-Receptor Antagonist
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast
  • 6.7 Fusion Inhibitors and Others
    • 6.7.1 Market Trends
    • 6.7.2 Market Forecast

7 Market Breakup by Distribution Channel

  • 7.1 Hospital Pharmacies
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Retail Pharmacies
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Online Pharmacies
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Others
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by Region

  • 8.1 North America
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Europe
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Asia Pacific
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Middle East and Africa
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Latin America
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast

9 HIV Drugs Manufacturing Process

  • 9.1 Product Overview
  • 9.2 Raw Material Requirements
  • 9.3 Manufacturing Process
  • 9.4 Key Success and Risk Factors

10 Competitive Landscape

  • 10.1 Market Structure
  • 10.2 Market Breakup by Key Players
  • 10.3 Profiles of Key Players
    • 10.3.1 Boehringer Ingelheim International GmbH
    • 10.3.2 Merck & Co., Inc.
    • 10.3.3 ViiV Healthcare
    • 10.3.4 AbbVie
    • 10.3.5 F. Hoffmann-La Roche Ltd.
    • 10.3.6 Teva Pharmaceutical Industries Ltd.
    • 10.3.7 Bristol-Myers Squibb
    • 10.3.8 Gilead Sciences, Inc.
    • 10.3.9 Johnson & Johnson
    • 10.3.10 Cipla Limited
    • 10.3.11 Daiichi Sankyo
    • 10.3.12 Emcure
    • 10.3.13 Hetero Drugs
    • 10.3.14 Mylan
Back to Top